PharVision Advisers’s Park National Corp PRK Stock Holding History

PharVision Advisers’s Portfolio PRK Stock Details PRK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-1,305	Closed	-$212K	–	941
2025 Q3	$212K	Buy	+1,305	New	+$220K	0.12%	465

Other funds holding PRK

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PNC

Park National Corp Newark, Ohio $3.57B AUM 22.83% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

PharVision Advisers's PRK Position: Q4 2025 in Review

PharVision Advisers sold out of Park National Corp (PRK) in Q4 2025, closing a stake of 1,305 shares — an estimated $212K sold.

PharVision Advisers first reported a position in PRK in Q3 2025 and held it in 1 quarter. The position peaked at $212K in Q3 2025. 269 funds tracked by Wall St. Rank hold PRK as of Q4 2025.

PharVision Advisers reported no remaining Park National Corp position as of Q4 2025 after selling out during the quarter.
PharVision Advisers sold 1,305 Park National Corp shares in Q4 2025, an estimated $212K.
PharVision Advisers first reported a position in Park National Corp in Q3 2025 and held it in 1 quarter.
PharVision Advisers's Park National Corp position peaked at $212K in Q3 2025.
269 funds tracked by Wall St. Rank held Park National Corp as of Q4 2025.

Based on PharVision Advisers's 13F filing for Q4 2025, filed 17 Feb 2026.